DANBURY, Conn., March 30, 2011 /PRNewswire/ — Biodel Inc.
(Nasdaq:
BIOD) announced today the appointment of Dr. Brian J.G. Pereira
as board chairman effective immediately. Dr. Pereira has
served on the board since November 2007. Dr. Charles A.
Sanders, who served as chairman since March 2010 after joining the
board in August 2006, will continue to serve as a board member
pending his return from medical leave.
Dr. Sanders stated: “The board and I welcome Dr. Pereira as
chairman. We are confident his leadership, experience and
continued commitment will ensure the future success of our
company.”
Dr. Pereira stated: “I thank the board for their confidence in
me as Biodel makes important steps forward in its development
program. I join the board in thanking Dr. Sanders for his
guidance and leadership.”
About Biodel Inc.
Biodel Inc. is a specialty biopharmaceutical company focused on
the development and commercialization of innovative treatments for
diabetes that may be safer, more effective and more convenient for
patients. We develop our product candidates by applying our
proprietary formulation technologies to existing drugs in order to
improve their therapeutic profiles. For further information
regarding Biodel, please visit the company’s website at www.biodel.com.
Safe-Harbor Statement
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such forward-looking statements include statements
about future activities related to the clinical development plans
for the company’s drug candidates, including the potential timing,
design and outcomes of clinical trials; and the company’s ability
to develop and commercialize product candidates.
Forward-looking statements represent our
‘/>”/>
SOURCE
